IN8bio, Inc. (INAB): Price and Financial Metrics

IN8bio, Inc. (INAB): $0.25

0.01 (+3.49%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

C

Add INAB to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#177 of 338

in industry

INAB Price/Volume Stats

Current price $0.25 52-week high $1.93
Prev. close $0.24 52-week low $0.22
Day low $0.23 Volume 1,329,700
Day high $0.26 Avg. volume 560,674
50-day MA $0.30 Dividend yield N/A
200-day MA $0.71 Market Cap 18.03M

INAB Stock Price Chart Interactive Chart >


IN8bio, Inc. (INAB) Company Bio


IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. The company develops INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. It also develops INB-400 and INB-300 that is in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.


INAB Latest News Stream


Event/Time News Detail
Loading, please wait...

INAB Latest Social Stream


Loading social stream, please wait...

View Full INAB Social Stream

INAB Price Returns

1-mo -21.88%
3-mo -20.46%
6-mo -71.64%
1-year -79.84%
3-year -96.06%
5-year N/A
YTD -81.88%
2023 -40.26%
2022 -47.38%
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!